|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 500 NEW JERSEY AVENUE, NW, #350 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Princeton |
State | NJ |
Zip Code | 08540 |
Country | USA |
|
5. Senate ID# 284790-12
|
||||||||
|
6. House ID# 369030000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Michael L. Mawby, Chief Government Affairs Officer |
Date | 07/18/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 2638 and S. 1644, Homeland Security Appropriations Act, drug importation provisions; H.R. 3043 and S. 1710, Labor-HHS-Education and Related Agencies Appropriations Act, drug importation and diabetes provisions; H.R. 3161 and S. 1859, Agriculture, Rural Development, Food and Drug Administration Appropriations Act, drug importation provisions; H.R. 3093 and S. 1745, Commerce, Justice, Science and Related Agencies Appropriations Act, drug importation provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Christopher |
Porter |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
Legislative Director, Rep. Cliff Stearns |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 1908 and S. 1145, Patent Reform Act of 2007 (entire bill)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Christopher |
Porter |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
Legislative Director, Rep. Cliff Stearns |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Legislation to reduce health diaparties, including H.R. 3014, the Healthcare Equity and Accountability Act, and S. 1576, Minority Health Improvement and Health Disparity Elimination Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Christopher |
Porter |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
Legislative Director, Rep. Cliff Stearns |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Protecting patient safety in H.R. 1038 and S. 623, Access to Life-Savings Medcine Act; H.R. 1956, Patient Protection and Innovative Biologics Medcines Act of 2007; S. 1505, Affordable Biologics for Consumers Act of 2007; S. 1695, Biologics Pirce Competition and Innovation Act of 2007; H.R. 5629, Pathway for Biosimilars Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Christopher |
Porter |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuks |
|
Legislative Director, Rep. Cliff Stearns |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3162, Children's Health and Medicare Protection Act of 2007; S. 2499, Medicare, Medicaid, and SCHIP Extension Act of 2007; H.R. 4/S. 3, Medicare Prescription Drug Price Negotiation Act; H.R. 2058, Helping Fill the Medicare Rx Gap Act of 2007; issues relating to comparative effectiveness
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Christopher |
Porter |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
Legislative Director, Rep. Cliff Stearns |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Improve the care and treatment of people with diabetes in H.R. 4836 and S. 2742, the National Diabetes Coordinator Act; H.R. 3544 and S. 2479, Catalyst for Better Diabetes Care Act; H.R. 2922 and S. 1302 (partial), the Preventing Diabetes in Medicare Act; H.R. 2762 and H.R. 1494, Reauthorize Special Diabetes Programs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Christopher |
Porter |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
Legislative Director, Rep. Cliff Stearns |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 3610, Foreign Facility FDA Inspection User Fees; H.R. 1585, National Defense Authorization (portions relating to Tricare); protecting patient access in S. 877, Controlling the Abuse of Prescriptions Act; S. 2029, Physician Payments Sunshine Act of 2007; S. 1376, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Christopher |
Porter |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
Legislative Director, Rep. Cliff Stearns |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
S.3123, Closing the Foreign Lobbying Loophole Act; H.R. 4854, False Claims Corrections Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mawby |
|
|
|
Steve |
McGill |
|
|
|
Christopher |
Porter |
|
|
|
Christopher |
McGowen |
|
|
|
Lauren |
Semeniuk |
|
Legislative Director, Rep. Cliff Stearns |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |